Atlas Trials

Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.

Clinical trial NCT05303129 · COMPLETED

Trial details

NCT number
NCT05303129
Sponsor
Centre Francois Baclesse
Status
COMPLETED
Phase
Not Applicable
Study type
INTERVENTIONAL
Breast CancerMetastatic Breast Cancer
Start date
2022-05-27
Primary completion
2024-12-17
Enrollment
165

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.